What is the Purpose of this Study?
Primary: Evaluate the safety and tolerability and identify recommended dose(s) for expansion (RDEs) of SNV4818 in adult participants with solid tumors as monotherapy and in combination with other anticancer agents. Secondary: 1. Characterize the PK profile of SNV4818 following oral administration as monotherapy. 2. Evaluate preliminary antitumor activity of SNV4818 in participants with select solid tumors as monotherapy and in combination with other anticancer agents.
Eligibility
- * Advanced or metastatic solid tumor with an activating PIK3CA mutation.
- * Refractory to or intolerant of available therapies
- * Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood.
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Where can I participate?
CS Cancer at The Angeles Clinic and Research Institute
More about this Clinical Trial
What is the full name of this clinical trial?
SNV4818-101: A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination with other Anticancer Agents in Participants with Advanced Solid Tumors